Maxell Ltd. v. Huawei Device U.S. Inc.

297 F. Supp. 3d 668
CourtDistrict Court, E.D. Texas
DecidedJanuary 31, 2018
DocketCIVIL ACTION NO. 5:16–CV–00178–RWS; CIVIL ACTION NO. 5:16–CV–00179–RWS
StatusPublished
Cited by2 cases

This text of 297 F. Supp. 3d 668 (Maxell Ltd. v. Huawei Device U.S. Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Maxell Ltd. v. Huawei Device U.S. Inc., 297 F. Supp. 3d 668 (E.D. Tex. 2018).

Opinion

ROBERT W. SCHROEDER III, UNITED STATES DISTRICT JUDGE

*677On November 29, 2017, the Court held an oral hearing to determine the proper construction of the disputed claim terms of the patents-in-suit. Having considered the parties claim-construction briefing and based on the intrinsic and extrinsic evidence, the Court construes the disputed terms in this Memorandum and Order as detailed below. See Phillips v. AWH Corp. , 415 F.3d 1303 (Fed. Cir. 2005) ; Teva Pharm. USA, Inc. v. Sandoz, Inc. , --- U.S. ----, 135 S.Ct. 831, --- L.Ed.2d ---- (2015).

BACKGROUND

On November 18, 2016, Plaintiff Maxell, Ltd. ("Maxell") filed suit against Defendants Huawei Device USA Inc., Huawei Device Co., Ltd. (collectively "Huawei") and ZTE USA Inc. ("ZTE"). Plaintiff Maxell, Ltd. ("Maxell") has asserted fifteen patents in this consolidated action:1

U.S. Patent No. 5,396,443 ("'443 Patent"), which is asserted against both Huawei and ZTE USA;
• U.S. Patent Nos. 7,509,139 ("'139 Patent") ; 6,754,440 ("'440 Patent") ; 6,928,292 ("'292 Patent") ; 7,203,517 ("'517 Patent") ; 7,671,901 ("'901 Patent") ; 6,856,760 ("'760 Patent") ; and 7,116,438 ("'438 Patent"), which are asserted against Huawei; and
• U.S. Patent Nos. 6,748,317 ("'317 Patent") ; 8,339,493 ("'493 Patent") ; 8,736,729 ("'729 Patent") ; 6,408,193 ("'193 Patent") ; 6,329,794 ("'794 Patent") ; 6,816,491 ("'491 Patent") ; and 8,098,695 ("'695 Patent"), which are asserted against ZTE USA.

On November 29, 2017, the Court held a Markman hearing on the disputed claim terms of the patents-in-suit. Docket Nos. 118, 138. At the hearing, Maxell and Huawei agreed to the construction of the sole disputed terms in the '901 Patent and '438 Patent. Docket No. 138 (H'rg Tr.) at 101:8-10.

APPLICABLE LAW

"It is a 'bedrock principle' of patent law that 'the claims of a patent define the invention to which the patentee is entitled the right to exclude.' " Phillips v. AWH Corp. , 415 F.3d 1303, 1312 (Fed. Cir. 2005) (en banc) (quoting Innova/Pure Water Inc. v. Safari Water Filtration Sys., Inc. , 381 F.3d 1111, 1115 (Fed. Cir. 2004) ). The Court examines a patent's intrinsic evidence to define the patented invention's scope. Id. at 1313-14 ; Bell Atl. Network Servs., Inc. v. Covad Commc'ns Group, Inc. , 262 F.3d 1258, 1267 (Fed. Cir. 2001). Intrinsic evidence includes the claims, the rest of the specification and the prosecution history. Phillips , 415 F.3d at 1312-13 ; Bell Atl. Network Servs. , 262 F.3d at 1267. The Court gives claim terms their ordinary and customary meaning as understood by one of ordinary skill in the art at the time of the invention. Phillips , 415 F.3d at 1312-13 ; Alloc, Inc. v. Int'l Trade Comm'n , 342 F.3d 1361, 1368 (Fed. Cir. 2003).

*678Claim language guides the Court's construction of claim terms. Phillips , 415 F.3d at 1314. "[T]he context in which a term is used in the asserted claim can be highly instructive." Id. Other claims, asserted and unasserted, can provide additional instruction because "terms are normally used consistently throughout the patent." Id. Differences among claims, such as additional limitations in dependent claims, can provide further guidance. Id.

"[C]laims 'must be read in view of the specification, of which they are a part.' " Id. (quoting Markman v. Westview Instruments, Inc. , 52 F.3d 967, 979 (Fed. Cir. 1995) ). "[T]he specification 'is always highly relevant to the claim construction analysis. Usually, it is dispositive; it is the single best guide to the meaning of a disputed term.' " Id. (quoting Vitronics Corp. v. Conceptronic, Inc. , 90 F.3d 1576, 1582 (Fed. Cir. 1996) ); Teleflex, Inc. v. Ficosa N. Am. Corp. , 299 F.3d 1313, 1325 (Fed. Cir. 2002). In the specification, a patentee may define his own terms, give a claim term a different meaning that it would otherwise possess, or disclaim or disavow some claim scope. Phillips , 415 F.3d at 1316. Although the Court generally presumes terms possess their ordinary meaning, this presumption can be overcome by statements of clear disclaimer. See SciMed Life Sys., Inc. v. Advanced Cardiovascular Sys., Inc. , 242 F.3d 1337, 1343-44 (Fed. Cir. 2001). This presumption does not arise when the patentee acts as his own lexicographer. See

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
297 F. Supp. 3d 668, Counsel Stack Legal Research, https://law.counselstack.com/opinion/maxell-ltd-v-huawei-device-us-inc-txed-2018.